Tralokinumab

Status:

Red

Decision Date:

September 2022

Comments

RED: NICE TA814 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis.

Adults commissioned by ICS. Adolescents commissioned by NHSE.

search again